版本:
中国

BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab)

May 17 Bristol-Myers Squibb Co

* Health Canada approves opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck

* Bristol- Myers Squibb Co says data to support approval was based on Checkmate-141, a phase three clinical trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐